PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
KRYS vs. CAMT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between KRYS and CAMT is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

KRYS vs. CAMT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Krystal Biotech, Inc. (KRYS) and Camtek Ltd (CAMT). The values are adjusted to include any dividend payments, if applicable.

-40.00%-30.00%-20.00%-10.00%0.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-27.08%
-16.58%
KRYS
CAMT

Key characteristics

Sharpe Ratio

KRYS:

0.24

CAMT:

0.59

Sortino Ratio

KRYS:

0.96

CAMT:

1.14

Omega Ratio

KRYS:

1.11

CAMT:

1.14

Calmar Ratio

KRYS:

0.42

CAMT:

0.70

Martin Ratio

KRYS:

1.08

CAMT:

1.20

Ulcer Index

KRYS:

12.99%

CAMT:

28.14%

Daily Std Dev

KRYS:

58.07%

CAMT:

57.56%

Max Drawdown

KRYS:

-53.42%

CAMT:

-97.74%

Current Drawdown

KRYS:

-31.46%

CAMT:

-31.89%

Fundamentals

Market Cap

KRYS:

$4.21B

CAMT:

$4.24B

EPS

KRYS:

$1.79

CAMT:

$2.18

PE Ratio

KRYS:

81.81

CAMT:

42.88

Total Revenue (TTM)

KRYS:

$199.38M

CAMT:

$311.94M

Gross Profit (TTM)

KRYS:

$182.28M

CAMT:

$151.72M

EBITDA (TTM)

KRYS:

$51.83M

CAMT:

$82.38M

Returns By Period

In the year-to-date period, KRYS achieves a -6.52% return, which is significantly lower than CAMT's 15.74% return.


KRYS

YTD

-6.52%

1M

-12.63%

6M

-29.36%

1Y

15.35%

5Y*

23.19%

10Y*

N/A

CAMT

YTD

15.74%

1M

20.99%

6M

-17.62%

1Y

28.35%

5Y*

50.32%

10Y*

40.90%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

KRYS vs. CAMT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KRYS
The Risk-Adjusted Performance Rank of KRYS is 6161
Overall Rank
The Sharpe Ratio Rank of KRYS is 5757
Sharpe Ratio Rank
The Sortino Ratio Rank of KRYS is 6161
Sortino Ratio Rank
The Omega Ratio Rank of KRYS is 5757
Omega Ratio Rank
The Calmar Ratio Rank of KRYS is 6767
Calmar Ratio Rank
The Martin Ratio Rank of KRYS is 6161
Martin Ratio Rank

CAMT
The Risk-Adjusted Performance Rank of CAMT is 6767
Overall Rank
The Sharpe Ratio Rank of CAMT is 6969
Sharpe Ratio Rank
The Sortino Ratio Rank of CAMT is 6565
Sortino Ratio Rank
The Omega Ratio Rank of CAMT is 6464
Omega Ratio Rank
The Calmar Ratio Rank of CAMT is 7575
Calmar Ratio Rank
The Martin Ratio Rank of CAMT is 6262
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

KRYS vs. CAMT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Camtek Ltd (CAMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for KRYS, currently valued at 0.24, compared to the broader market-2.000.002.000.240.59
The chart of Sortino ratio for KRYS, currently valued at 0.96, compared to the broader market-4.00-2.000.002.004.000.961.14
The chart of Omega ratio for KRYS, currently valued at 1.11, compared to the broader market0.501.001.502.001.111.14
The chart of Calmar ratio for KRYS, currently valued at 0.42, compared to the broader market0.002.004.006.000.420.70
The chart of Martin ratio for KRYS, currently valued at 1.08, compared to the broader market-30.00-20.00-10.000.0010.0020.001.081.20
KRYS
CAMT

The current KRYS Sharpe Ratio is 0.24, which is lower than the CAMT Sharpe Ratio of 0.59. The chart below compares the historical Sharpe Ratios of KRYS and CAMT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.000.501.001.502.002.503.003.50AugustSeptemberOctoberNovemberDecember2025
0.24
0.59
KRYS
CAMT

Dividends

KRYS vs. CAMT - Dividend Comparison

KRYS has not paid dividends to shareholders, while CAMT's dividend yield for the trailing twelve months is around 1.42%.


TTM20242023202220212020201920182017
KRYS
Krystal Biotech, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
CAMT
Camtek Ltd
1.42%1.65%0.00%0.00%0.00%0.00%1.57%2.07%2.45%

Drawdowns

KRYS vs. CAMT - Drawdown Comparison

The maximum KRYS drawdown since its inception was -53.42%, smaller than the maximum CAMT drawdown of -97.74%. Use the drawdown chart below to compare losses from any high point for KRYS and CAMT. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-31.46%
-31.89%
KRYS
CAMT

Volatility

KRYS vs. CAMT - Volatility Comparison

Krystal Biotech, Inc. (KRYS) has a higher volatility of 13.32% compared to Camtek Ltd (CAMT) at 12.45%. This indicates that KRYS's price experiences larger fluctuations and is considered to be riskier than CAMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%AugustSeptemberOctoberNovemberDecember2025
13.32%
12.45%
KRYS
CAMT

Financials

KRYS vs. CAMT - Financials Comparison

This section allows you to compare key financial metrics between Krystal Biotech, Inc. and Camtek Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab